301509 金凯生科
已收盘 10-08 15:00:00
资讯
新帖
简况
金凯生科（301509）9月23日主力资金净买入53.32万元
证券之星 · 09-24
金凯生科（301509）9月23日主力资金净买入53.32万元
股市必读：金凯生科(301509)股东户数1.52万户，较上期增加1.17%
证券之星 · 09-22
股市必读：金凯生科(301509)股东户数1.52万户，较上期增加1.17%
金凯生科：截至2026年9月18日，公司股东数为15,214户
证券之星 · 09-21
金凯生科：截至2026年9月18日，公司股东数为15,214户
9月15日金凯生科发布公告，股东减持37.01万股
证券之星 · 09-15
9月15日金凯生科发布公告，股东减持37.01万股
金凯生科(301509)8月31日股东户数1.5万户，较上期减少4.01%
证券之星 · 09-03
金凯生科(301509)8月31日股东户数1.5万户，较上期减少4.01%
股市必读：金凯生科中报 - 第二季度单季净利润同比下降44.01%
证券之星 · 08-24
股市必读：金凯生科中报 - 第二季度单季净利润同比下降44.01%
金凯生科（301509）2026年中报简析：净利润同比下降57.81%，公司应收账款体量较大
证券之星 · 08-22
金凯生科（301509）2026年中报简析：净利润同比下降57.81%，公司应收账款体量较大
破发股金凯生科跌5.72% 2023上市超募3.1亿中信建投保荐
中金财经 · 08-21
破发股金凯生科跌5.72% 2023上市超募3.1亿中信建投保荐
股市必读：金凯生科新发布《第二届董事会第十四次会议决议公告》
证券之星 · 08-21
股市必读：金凯生科新发布《第二届董事会第十四次会议决议公告》
金凯生科(301509)8月10日股东户数1.57万户，较上期增加12.92%
证券之星 · 08-20
金凯生科(301509)8月10日股东户数1.57万户，较上期增加12.92%
金凯生科(301509.SZ)发布上半年业绩，归母净利润3027.25万元，同比下降57.81%
智通财经 · 08-20
金凯生科(301509.SZ)发布上半年业绩，归母净利润3027.25万元，同比下降57.81%
金凯生科：公司目前业务不涉及CAR-T细胞疗法相关领域
证券之星 · 08-18
金凯生科：公司目前业务不涉及CAR-T细胞疗法相关领域
破发股金凯生科跌3.11% 2023上市超募3.1亿中信建投保荐
中金财经 · 08-17
破发股金凯生科跌3.11% 2023上市超募3.1亿中信建投保荐
股市必读：金凯生科(301509)股东户数1.57万户，较上期增加12.92%
证券之星 · 08-12
股市必读：金凯生科(301509)股东户数1.57万户，较上期增加12.92%
金凯生科：截至2026年8月10日，公司股东数为15,666户
证券之星 · 08-11
金凯生科：截至2026年8月10日，公司股东数为15,666户
金凯生科(301509)7月31日股东户数1.39万户，较上期减少0.45%
证券之星 · 08-04
金凯生科(301509)7月31日股东户数1.39万户，较上期减少0.45%
金凯生科：截至2026年7月31日，公司股东数为13,874户
证券之星 · 08-04
金凯生科：截至2026年7月31日，公司股东数为13,874户
金凯生科（301509）披露向2026年限制性股票与股票增值权激励计划激励对象首次授予限制性股票及股票增值权的公告，7月27日股价上涨3.44%
证券之星 · 07-27
金凯生科（301509）披露向2026年限制性股票与股票增值权激励计划激励对象首次授予限制性股票及股票增值权的公告，7月27日股价上涨3.44%
股市必读：金凯生科(301509)股东户数1.39万户，较上期减少0.21%
证券之星 · 07-23
股市必读：金凯生科(301509)股东户数1.39万户，较上期减少0.21%
金凯生科（301509）披露2026年限制性股票与股票增值权激励计划首次授予激励对象名单核查及公示情况，7月21日股价下跌6.81%
证券之星 · 07-21
金凯生科（301509）披露2026年限制性股票与股票增值权激励计划首次授予激励对象名单核查及公示情况，7月21日股价下跌6.81%
加载更多
公司概况
公司名称：
金凯(辽宁)生命科技股份有限公司
所属行业：
医药制造业
上市日期：
2023-08-03
主营业务：
金凯(辽宁)生命科技股份有限公司的主营业务是提供小分子药物中间体以及少量原料药的定制研发生产服务。公司的主要产品是中间体。
发行价格：
56.56
{"stockData":{"symbol":"301509","market":"SZ","secType":"STK","nameCN":"金凯生科","latestPrice":30.36,"timestamp":1791443001000,"preClose":31.25,"halted":0,"volume":2663080,"delay":0,"changeRate":-0.0285,"floatShares":56740900,"shares":120000000,"eps":0.5258,"marketStatus":"已收盘","change":-0.89,"latestTime":"10-08 15:00:00","open":31.26,"high":31.87,"low":30.1,"amount":81491600,"amplitude":0.0566,"askPrice":30.43,"askSize":14,"bidPrice":30.35,"bidSize":45,"shortable":0,"etf":0,"ttmEps":0.5258,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791509400000},"marketStatusCode":5,"adr":0,"adjPreClose":31.25,"symbolType":"stock","openAndCloseTimeList":[[1791423000000,1791430200000],[1791435600000,1791442800000]],"highLimit":34.38,"lowLimit":28.13,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":120446669,"isCdr":false,"pbRate":1.77,"roa":"--","peRate":57.740586,"roe":"1.37%","epsLYR":0.87,"committee":0.376426,"marketValue":3657000000,"turnoverRate":0.0469,"status":1,"floatMarketCap":1723000000},"requestUrl":"/m/hq/s/301509","defaultTab":"news","newsList":[{"id":"2669430996","title":"金凯生科（301509）9月23日主力资金净买入53.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669430996","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669430996?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:07","pubTimestamp":1790212040,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，金凯生科报收于32.34元，上涨3.49%，换手率9.5%，成交量5.39万手，成交额1.75亿元。近5日资金流向一览见下表：金凯生科融资融券信息显示，融资方面，当日融资买入1494.05万元，融资偿还1261.64万元，融资净买入232.41万元。金凯生科主营业务：为全球知名原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定制研发生产服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400008932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669167500","title":"股市必读：金凯生科(301509)股东户数1.52万户，较上期增加1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167500","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669167500?lang=zh_cn&edition=full","pubTime":"2026-09-22 01:06","pubTimestamp":1790010379,"startTime":"0","endTime":"0","summary":"截至2026年9月21日收盘，金凯生科报收于30.98元，上涨3.75%，换手率6.89%，成交量3.91万手，成交额1.2亿元。当日关注点交易信息汇总：9月21日游资资金净流出1493.96万元，占总成交额12.41%。股本股东变化：截至2026年9月18日，金凯生科股东户数为1.52万户，较8月31日增加1.17%。股本股东变化股东户数变动截至2026年9月18日，金凯生科股东户数为1.52万户，较8月31日增加176.0户，增幅为1.17%；户均持股数量由上期的8009.0股减少至7917.0股，户均持股市值为23.64万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200000664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669134634","title":"金凯生科：截至2026年9月18日，公司股东数为15,214户","url":"https://stock-news.laohu8.com/highlight/detail?id=2669134634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669134634?lang=zh_cn&edition=full","pubTime":"2026-09-21 11:36","pubTimestamp":1789961795,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)09月20日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至9月10日的最新股东数？谢谢。金凯生科回复：尊敬的投资者，您好！截至2026年9月18日，公司股东数为15,214户。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100009978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667440146","title":"9月15日金凯生科发布公告，股东减持37.01万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667440146","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667440146?lang=zh_cn&edition=full","pubTime":"2026-09-15 20:01","pubTimestamp":1789473666,"startTime":"0","endTime":"0","summary":"证券之星消息，9月15日金凯生科发布公告《金凯生科:关于股东减持股份计划期间届满暨减持结果的公告》，其股东青岛青松创业投资集团有限公司-青岛松凯创业投资企业(有限合伙)、启鹭(厦门)股权投资合伙企业(有限合伙)于2026年6月15日至2026年8月20日间合计减持37.01万股，占公司目前总股本的0.3073%，变动期间该股股价上涨22.11%，截止8月20日收盘报32.69元。股东增减持详情见下表：根据金凯生科2026年中报公布的十大股东详情如下：本文数据来源于金凯生科公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500033777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664736298","title":"金凯生科(301509)8月31日股东户数1.5万户，较上期减少4.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664736298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664736298?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:39","pubTimestamp":1788428365,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金凯生科披露，截至2026年8月31日公司股东户数为1.5万户，较8月10日减少628.0户，减幅为4.01%。在医疗服务行业个股中，金凯生科股东户数低于行业平均水平，截至8月31日，医疗服务行业平均股东户数为4.78万户。从股价来看，2026年8月10日至2026年8月31日，金凯生科区间跌幅为7.75%，在此期间股东户数减少628.0户，减幅为4.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300032064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661924301","title":"股市必读：金凯生科中报 - 第二季度单季净利润同比下降44.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661924301","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661924301?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:29","pubTimestamp":1787506149,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年中报显示归母净利润3027.25万元，同比下降57.81%。业绩披露要点财务报告金凯生科2026年中报显示，上半年度公司主营收入3.09亿元，同比下降11.22%；归母净利润3027.25万元，同比下降57.81%；扣非净利润2302.51万元，同比下降61.09%；其中2026年第二季度，公司单季度主营收入1.61亿元，同比下降6.3%；单季度归母净利润1362.9万元，同比下降44.01%；单季度扣非净利润924.93万元，同比下降44.35%；负债率6.55%，投资收益554.26万元，财务费用726.88万元，毛利率38.63%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400000909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661218604","title":"金凯生科（301509）2026年中报简析：净利润同比下降57.81%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2661218604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661218604?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:17","pubTimestamp":1787350624,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期金凯生科发布2026年中报。截至本报告期末，公司营业总收入3.09亿元，同比下降11.22%，归母净利润3027.25万元，同比下降57.81%。按单季度数据看，第二季度营业总收入1.61亿元，同比下降6.3%，第二季度归母净利润1362.9万元，同比下降44.01%。本报告期金凯生科公司应收账款体量较大，当期应收账款占最新年报归母净利润比达103.67%。财报体检工具显示：建议关注公司应收账款状况本文数据来源于金凯生科2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200005315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661626507","title":"破发股金凯生科跌5.72% 2023上市超募3.1亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2661626507","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661626507?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:54","pubTimestamp":1787302446,"startTime":"0","endTime":"0","summary":"中国经济网北京8月21日讯 金凯生科 今日收报30.82元，跌幅5.72%。目前该股处于破发状态。 金凯生科于2023年8月3日在深交所创业板上市，发行股份数量为2,150.8335万股，发行股份占本次发行后公司股份总数的比例为25.00%，发行价格为56.56元/股。金凯生科本次发行的保荐机构为中信建投证券股份有限公司，保荐代表人为逯金才、张林。 金凯生科本次公开发行新股的发行费用合计10,576.71万元，其中中信建投证券股份有限公司获得保荐及承销费用8,654.56万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260821/32342832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","601066","BK0276","301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661023136","title":"股市必读：金凯生科新发布《第二届董事会第十四次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2661023136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661023136?lang=zh_cn&edition=full","pubTime":"2026-08-21 02:21","pubTimestamp":1787250070,"startTime":"0","endTime":"0","summary":"公司公告汇总第二届董事会第十四次会议决议公告2026年8月20日召开第二届董事会第十四次会议，审议通过《2026年半年度报告》及其摘要、《2026年半年度募集资金存放、管理与使用情况的专项报告》、使用部分闲置募集资金及自有资金进行现金管理、使用部分超募资金永久补充流动资金，以及提请召开2026年第二次临时股东会等议案，全部获全票通过；会议由董事长FUMIN WANG主持，审计委员会已审议通过相关议案，部分事项尚需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288385","title":"金凯生科(301509)8月10日股东户数1.57万户，较上期增加12.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288385","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660288385?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:39","pubTimestamp":1787218786,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金凯生科披露，截至2026年8月10日公司股东户数为1.57万户，较7月31日增加1792.0户，增幅为12.92%。在医疗服务行业个股中，金凯生科股东户数低于行业平均水平，截至8月10日，医疗服务行业平均股东户数为4.78万户。从股价来看，2026年7月31日至2026年8月10日，金凯生科区间涨幅为18.53%，在此期间股东户数增加1792.0户，增幅为12.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000031923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660003400","title":"金凯生科(301509.SZ)发布上半年业绩，归母净利润3027.25万元，同比下降57.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660003400","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660003400?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:37","pubTimestamp":1787218629,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金凯生科(301509.SZ)发布2026年半年度报告，报告期内，公司实现营业收入3.09亿元，同比下降11.22%。实现归属于上市公司股东的净利润3027.25万元，同比下降57.81%。实现归属于上市公司股东的扣除非经常性损益的净利润2302.51万元，同比下降61.09%。基本每股收益0.25元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660450291","title":"金凯生科：公司目前业务不涉及CAR-T细胞疗法相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2660450291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660450291?lang=zh_cn&edition=full","pubTime":"2026-08-18 15:54","pubTimestamp":1787039649,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司是否有涉及CAR-T细胞疗法方面的项目？金凯生科回复：尊敬的投资者，您好！公司目前业务不涉及CAR-T细胞疗法相关领域。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800024358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660148385","title":"破发股金凯生科跌3.11% 2023上市超募3.1亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2660148385","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660148385?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:14","pubTimestamp":1786954451,"startTime":"0","endTime":"0","summary":"中国经济网北京8月17日讯 金凯生科 今日收报32.75元，跌幅3.11%。目前该股处于破发状态。 金凯生科于2023年8月3日在深交所创业板上市，发行股份数量为2,150.8335万股，发行股份占本次发行后公司股份总数的比例为25.00%，发行价格为56.56元/股。金凯生科本次发行的保荐机构为中信建投证券股份有限公司，保荐代表人为逯金才、张林。 金凯生科本次公开发行新股的发行费用合计10,576.71万元，其中中信建投证券股份有限公司获得保荐及承销费用8,654.56万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260817/32337054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","601066","BK0276","301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658129089","title":"股市必读：金凯生科(301509)股东户数1.57万户，较上期增加12.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658129089","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658129089?lang=zh_cn&edition=full","pubTime":"2026-08-12 01:19","pubTimestamp":1786468749,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，金凯生科报收于32.04元，上涨0.56%，换手率10.24%，成交量5.81万手，成交额1.87亿元。当日关注点交易信息汇总：8月11日主力资金净流出1116.1万元，占总成交额5.98%。股本股东变化：截至2026年8月10日，金凯生科股东户数为1.57万户，较7月31日增加12.92%。股本股东变化股东户数变动截至2026年8月10日公司股东户数为1.57万户，较7月31日增加1792.0户，增幅为12.92%；户均持股数量由上期的8681.0股减少至7688.0股，户均持股市值为24.5万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200001605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658960305","title":"金凯生科：截至2026年8月10日，公司股东数为15,666户","url":"https://stock-news.laohu8.com/highlight/detail?id=2658960305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658960305?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:18","pubTimestamp":1786432701,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)08月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2026年8月10日，公司股东人数多少？金凯生科回复：尊敬的投资者，您好！截至2026年8月10日，公司股东数为15,666户。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100018998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656312995","title":"金凯生科(301509)7月31日股东户数1.39万户，较上期减少0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656312995","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656312995?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:53","pubTimestamp":1785837237,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金凯生科披露，截至2026年7月31日公司股东户数为1.39万户，较7月20日减少63.0户，减幅为0.45%。在医疗服务行业个股中，金凯生科股东户数低于行业平均水平，截至7月31日，医疗服务行业平均股东户数为4.87万户。从股价来看，2026年7月20日至2026年7月31日，金凯生科区间跌幅为10.73%，在此期间股东户数减少63.0户，减幅为0.45%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400030153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656583442","title":"金凯生科：截至2026年7月31日，公司股东数为13,874户","url":"https://stock-news.laohu8.com/highlight/detail?id=2656583442","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656583442?lang=zh_cn&edition=full","pubTime":"2026-08-04 08:36","pubTimestamp":1785803770,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科(301509)08月03日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问截止到7月31日收盘，公司股东人数有多少？谢谢金凯生科回复：尊敬的投资者，您好！截至2026年7月31日，公司股东数为13,874户。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400007746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654049853","title":"金凯生科（301509）披露向2026年限制性股票与股票增值权激励计划激励对象首次授予限制性股票及股票增值权的公告，7月27日股价上涨3.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654049853","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654049853?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:48","pubTimestamp":1785163696,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，金凯生科报收于27.68元，较前一交易日上涨3.44%，最新总市值为33.34亿元。金凯（辽宁）生命科技股份有限公司于近日向73名激励对象首次授予207.00万股限制性股票，授予价格为15.13元/股，占公司总股本的1.72%；同时向20名激励对象授予27.00万份股票增值权，占公司总股本的0.22%。本次授予的限制性股票与股票增值权的授予日均为2026年7月27日，激励对象包括董事、高级管理人员、中层管理人员及核心业务人员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700035257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653620857","title":"股市必读：金凯生科(301509)股东户数1.39万户，较上期减少0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653620857","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653620857?lang=zh_cn&edition=full","pubTime":"2026-07-23 01:51","pubTimestamp":1784742666,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，金凯生科报收于28.15元，上涨0.32%，换手率6.17%，成交量3.5万手，成交额1.0亿元。当日关注点交易信息汇总：7月22日主力资金净流入317.18万元，占总成交额0.0%。股本股东变化：截至2026年7月20日，金凯生科股东户数为1.39万户，较7月10日减少30.0户，减幅0.21%。户均持股数量由上期的8624.0股增加至8642.0股，户均持股市值为26.02万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300001810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301509","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653205604","title":"金凯生科（301509）披露2026年限制性股票与股票增值权激励计划首次授予激励对象名单核查及公示情况，7月21日股价下跌6.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653205604","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653205604?lang=zh_cn&edition=full","pubTime":"2026-07-21 22:20","pubTimestamp":1784643615,"startTime":"0","endTime":"0","summary":"金凯（辽宁）生命科技股份有限公司于2026年7月21日披露《董事会薪酬与考核委员会关于2026年限制性股票与股票增值权激励计划首次授予激励对象名单的核查意见及公示情况说明》。公告显示，公司于2026年7月11日至7月20日期间通过内部公示栏对2026年限制性股票与股票增值权激励计划首次授予激励对象的姓名及职务进行公示，员工可通过书面、电话、邮件等方式反馈意见；公示期内未收到任何异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100044650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301509"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791460458377,"stockEarnings":[{"period":"1week","weight":-0.0337},{"period":"1month","weight":0.0633},{"period":"3month","weight":0.0303},{"period":"6month","weight":-0.2344},{"period":"1year","weight":-0.1235},{"period":"ytd","weight":-0.0462}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"金凯(辽宁)生命科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15214人(较上一季度增加1.17%)","perCapita":"3729股","listingDate":"2023-08-03","address":"辽宁省阜新市阜新蒙古族自治县伊吗图镇氟化工园区安仁路6号","registeredCapital":"12044万元","survey":" 金凯(辽宁)生命科技股份有限公司的主营业务是提供小分子药物中间体以及少量原料药的定制研发生产服务。公司的主要产品是中间体。","listedPrice":56.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金凯生科(301509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金凯生科(301509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金凯生科,301509,金凯生科股票,金凯生科股票老虎,金凯生科股票老虎国际,金凯生科行情,金凯生科股票行情,金凯生科股价,金凯生科股市,金凯生科股票价格,金凯生科股票交易,金凯生科股票购买,金凯生科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金凯生科(301509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金凯生科(301509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}